


CLAIMS

- 5 where R^1 and R^2 each represent H, or together represent a second carbon-carbon bond
between the carbon atoms to which they are attached;
when R^1 and R^2 each represent H, then R^3 and R^4 also represent H;
when R^1 and R^2 together represent a second carbon-carbon bond between the
carbon atoms to which they are attached, then R^3 and R^4 independently represent H or C_{1-6}
10 alkyl;
Ar represents:
phenyl or naphthyl, which groups are optionally substituted by one or more groups
selected from C_{1-6} alkyl [which may itself be substituted by one or more substituents selected
from halo, C_{1-6} alkoxy, CO_2H , NH_2 , $NH(C_{1-6} \text{ alkyl})$, and $N(C_{1-6} \text{ alkyl})_2$], halo, C_{1-6} alkoxy, CO_2H ,
15 C_{1-6} alkoxycarbonyl, NO_2 , CN, NH_2 , $NH(C_{1-6} \text{ alkyl})$, $N(C_{1-6} \text{ alkyl})_2$, OH and C_{1-3} alkylenedioxy,
or
a 5- or 6-membered heteroaryl ring containing up to 4 heteroatoms selected from N,
O and S, which group is optionally substituted by one or more groups selected from C_{1-6} alkyl
[which may itself be substituted by one or more substituents selected from halo, C_{1-6} alkoxy,
20 CO_2H , NH_2 , $NH(C_{1-6} \text{ alkyl})$ and $N(C_{1-6} \text{ alkyl})_2$], halo, C_{1-6} alkoxy, CO_2H , C_{1-6} alkoxycarbonyl,
 NO_2 , CN, NH_2 , $NH(C_{1-6} \text{ alkyl})$ and $N(C_{1-6} \text{ alkyl})_2$;
or a veterinarily acceptable salt thereof;
in the manufacture of a medicament for the treatment or prophylaxis of an endothelin-
mediated disorder in a companion animal.
- 25 2. The use as claimed in claim 1, wherein the companion animal is as a cat, a
dog or a horse.
3. The use as claimed in claim 1 or claim 2, wherein the endothelin-mediated
disorder is hypertension, congestive heart failure or chronic renal failure.



4. The use as claimed in any one of the preceding claims, wherein R¹ and R² each represent H.

5. The use as claimed in any one of the preceding claims, wherein R³ and R⁴ each represent H.

5 6. The use as claimed in any one of the preceding claims, wherein Ar represents phenyl, naphthyl or thienyl, which groups are optionally substituted by one or more groups selected from C₁₋₆ alkyl, halo, CF₃, C₁₋₆ alkoxy, CO₂H and C₁₋₆ alkoxycarbonyl;

7. The use as claimed in any one of the preceding claims, wherein Ar is phenyl.

8. The use as claimed in any one of the preceding claims, wherein the use is for
10 manufacturing a medicament for the treatment of congestive heart failure in a dog.

9. The use as claimed in any one of claims 1 to 7, wherein the use is for manufacturing a medicament for the treatment of chronic renal failure in a cat.

10. A formulation containing a compound of formula I, as defined in claim 1, or a
veterinarily acceptable salt thereof, characterized in that it is adapted for administration to a
15 companion animal.

11. A formulation as claimed in claim 10, which is adapted for oral administration and has a taste attractive to the companion animal.

12 A method of treatment or prophylaxis of an endothelin-mediated disorder in a
companion animal, which comprises administering an effective amount of a compound of
20 formula I, as defined in claim 1, or a veterinarily acceptable salt thereof, to the companion
animal.

13. ~~A pharmaceutical pack comprising a formulation according to claim 10 or 11 and instructions describing the treatment of congestive heart failure in a dog.~~

14. A pharmaceutical pack comprising a formulation according to claim 10 or 11
25 and instructions describing the treatment of chronic renal failure in a cat.

Sub
B3
cont.

THE UNIVERSITY OF CHICAGO

ins.
R4